Journal of Gastrointestinal Surgery

, Volume 14, Issue 12, pp 1859–1866 | Cite as

Perioperative Anti-Tumor Necrosis Factor Therapy Does Not Increase the Rate of Early Postoperative Complications in Crohn’s Disease

  • Basil S. Nasir
  • Eric J. Dozois
  • Robert R. Cima
  • John H. Pemberton
  • Bruce G. Wolff
  • William J. Sandborn
  • Edward V. Loftus
  • David W. Larson
2010 SSAT Plenary Presentation



There have been numerous studies with conflicting results regarding the use of anti-tumor necrosis factor (TNF) therapy and its relationship to postoperative outcome in Crohn disease. The aim of our study was to examine the rate of postoperative morbidity in patients receiving anti TNF therapy in the perioperative period.


All patients undergoing surgery for Crohn disease from 2005 till 2008 were abstracted from a prospective database. Patients undergoing surgery which included a suture or staple line at risk for leaking were selected for the study. A retrospective review of medical records was performed. The study group comprised patients treated with perioperative anti TNF therapy (defined as treatment within 8 weeks preoperatively or up to 30 days postoperatively). The remainder of the patients did not receive perioperative anti TNF therapy. Patient characteristics, disease severity, medication use, operative intervention and 30-day complication were compared between the two groups.


Three hundred and seventy patients were selected for analysis in this study, of which 119 received perioperative anti TNF therapy and 251 did not. The groups were similar in baseline characteristics, perioperative risk factors and procedures. The group who received perioperative anti TNF therapy had a more severe disease overall as measured by the American College of Gastroenterology (ACG) categories of disease (50% severe fulminant disease in the perioperative anti-TNF therapy group versus 18% in the group that did not receive perioperative anti-TNF therapy, p < 0.001). There was no significant association of perioperative anti TNF therapy and any postoperative complications (27.9% in anti-TNF group versus 30.1% in no anti-TNF group, p = 0.63) nor intra-abdominal infectious complications (5.0% in anti-TNF group versus 7.2% in no anti-TNF group, p = 0.44). Univariate analysis showed that the only factors associated with an increase in postoperative intra-abdominal infections were age and penetrating disease.


The use of anti-TNF therapy in the perioperative period is safe and is not associated with an increase in overall or infectious complications in Crohn disease patients undergoing surgery.


Crohn's disease Anti-tumor necrosis factor Postoperative complications Infliximab 


  1. 1.
    Lictenstein GR, Hanauer SB, Sandborn WJ. ACG practice guidelines: Management of Crohn's Disease in Adults. Am J Gastroenterol 2009; 104:465–483CrossRefGoogle Scholar
  2. 2.
    Solem CA, Loftus EV Jr. Management of refractory inflammatory bowel disease. Gastroenterol Clin N Am. 2004; 33:319–334CrossRefGoogle Scholar
  3. 3.
    Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens G, Diamond RH, Broussard DL, Tang KL, van der Woude CJ, Rutgeerts P. Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease. N Engl J Med 2010; 362:1383-95CrossRefPubMedGoogle Scholar
  4. 4.
    Sandborn WJ, Loftus EV. Balancing the risks and benefits of inflixmab in the treatment of inflammatory bowel disease. Gut. 2004; 53:780-782CrossRefPubMedGoogle Scholar
  5. 5.
    Reguiiro M, Schraut W, Baidoo L, Kip KE, Sepluveda AR, Pesci M, Harrison J, Plevy SE. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenetrology 2009; 136(2):441-30CrossRefGoogle Scholar
  6. 6.
    Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD, Pollack PF. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007;132(1):52-65CrossRefPubMedGoogle Scholar
  7. 7.
    Ghosh S, Goldin E, Gordon FH, Malchow HA, Rask-Madsen J, Rutgeerts P, Vyhnalek P, Zadorova Z, Palmer T, Donoghue S. Natalizumab for Active Crohn's Disease. N Engl J Med 2003; 348:24-32CrossRefPubMedGoogle Scholar
  8. 8.
    Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, Bloomfield R, Schreiber S. Certolizumab Pegol for the Treatment of Crohn's Disease. N Engl J Med 2007; 357:228-38CrossRefPubMedGoogle Scholar
  9. 9.
    Colombel JF, Loftus EV Jr, Tremaine WJ, Pemberton JH, Wolff BG, Young-Fadok T, Harmsen WS, Schelck CD, Sandborn WJ. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol. 2004; 99(5):878-83.CrossRefPubMedGoogle Scholar
  10. 10.
    Appau KA, Fazio VW, Shen B, Church JM, Lashner B, Remzi F, Brzezinski A, Strong SA, Hammel J, Kiran RP. Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn's patients. J Gastrointest Surg. 2008;12(10):1738-44CrossRefPubMedGoogle Scholar
  11. 11.
    Kunitake H, Hodin R, Shellito PC, Sands BE, Korzenik J, Bordeianou L. Perioperative treatment with infliximab in patients with Crohn's disease and ulcerative colitis is not associated with an increased rate of postoperative complications. J Gastrointest Surg 2008; 12(10): 1730-6CrossRefPubMedGoogle Scholar
  12. 12.
    Ferrante M, D'Hoore A, Vermeire S, Declerck S, Noman M, Van Assche G, Hoffman I, Rutgeerts P, Penninck F. Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis. Inflamm Bowel Dis. 2009; 15(7):1062-70CrossRefPubMedGoogle Scholar
  13. 13.
    Bordeianou L. In flux on infliximab: conflicting studies on surgical outcomes. Inflamm Bowel Dis. 2009; 15(10):1605-6CrossRefPubMedGoogle Scholar
  14. 14.
    Selvasekar CR, Cima RR, Larson DW, Dozois EJ, Harrington JR, Harmsen WS, Loftus EV Jr, Sandborn WJ, Wolff BG, Pemberton JH. Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg. 2007; 204(5):956-62CrossRefPubMedGoogle Scholar
  15. 15.
    Subramanian V, Saxena S, Kang JY, Pollok RC. Preoperative Steroid Use and Risk of Postoperative Complications in Patients with Inflammatory Bowel Disease Undergoing Abdominal Surgery. Am J Gastroenterol 2008; 103(9): 2372-81CrossRefGoogle Scholar
  16. 16.
    Remicade (infliximab) for IV injection. Package insert, Centocor Inc., Malvern, PA. 2009Google Scholar
  17. 17.
    Humira (adalimumab) full prescribing information, Abbott Labaratories: Abbott Park, IL. 2010
  18. 18.
    Cimzia (certolizumab) full prescribing information, UCB Inc.: Smyrna, GA. 2010

Copyright information

© The Society for Surgery of the Alimentary Tract 2010

Authors and Affiliations

  • Basil S. Nasir
    • 1
  • Eric J. Dozois
    • 1
  • Robert R. Cima
    • 1
  • John H. Pemberton
    • 1
  • Bruce G. Wolff
    • 1
  • William J. Sandborn
    • 2
  • Edward V. Loftus
    • 2
  • David W. Larson
    • 1
    • 3
  1. 1.Division of Colon and Rectal SurgeryMayo Clinic College of MedicineRochesterUSA
  2. 2.Division of Gastroenterology and HepatologyMayo Clinic College of MedicineRochesterUSA
  3. 3.Division of Colorectal Surgery, Department of SurgeryMayo Clinic College of MedicineRochesterUSA

Personalised recommendations